Trials@uspto.gov Paper 66
Tel: 571-272-7822 Entered: June 21, 2018

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ILLUMINA, INC., Petitioner,

v.

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, Patent Owner.

Case IPR2018-00291 (Patent 9,718,852 B2)

Case IPR2018-00318 (Patent 9,719,139 B2)

Case IPR2018-00322 (Patent 9,708,358 B2)

Case IPR2018-00385 (Patent 9,725,480 B2)1

Before JAMES A. WORTH, MICHELLE N. ANKENBRAND, and BRIAN D. RANGE, *Administrative Patent Judges*.

Opinion for the Board *per curiam*. Opinion Dissenting filed by Administrative Patent Judge WORTH.

Per curiam

entered into each proceeding and the paper contains a footnote indicating the same.



The proceedings have not been consolidated. The parties are not authorized to use a combined caption unless an identical paper is being

FINAL WRITTEN DECISION 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73

I. INTRODUCTION

This is a Final Written Decision addressing four *inter partes* reviews challenging each claim of U.S. Patent Nos. 9,718,852 B2 ("the '852 patent"), 9,719,139 B2 ("the '139 patent"), 9,708,358 B2 ("the '358 patent"), and 9,725,480 B2 ("the '480 patent"). We have jurisdiction under 35 U.S.C. § 6. For the reasons that follow, we determine that Illumina, Inc. ("Petitioner" or "Illumina") demonstrates, by a preponderance of the evidence, that the challenged claims are unpatentable.

A. Procedural History

Petitioner filed four Petitions (Paper 1,² "Pet.") requesting an *inter* partes review of the '852 patent, the '139 patent, the '358 patent, and the '480 patent. We instituted trial on the following grounds:³

Patent	References	Basis	Claim Challenged
'852	Tsien, ⁴ Prober ⁵	§ 103(a)	1

James M. Prober et al., A System for Rapid DNA Sequencing with Fluorescent Chain-Terminating Dideoxynucleotides, 238 SCIENCE 336–341 (Oct. 16, 1987) ("Prober") (Ex. 1014).



Unless this opinion otherwise indicates, all citations are to IPR2018-00291 ("the '291 IPR").

³ See IPR2018-00291, Paper 16 (June 25, 2018); IPR2018-00318, Paper 16 (July 2, 2018); IPR2018-00322, Paper 16 (July 2, 2018); IPR2018-00385, Paper 20 (July 26, 2018).

⁴ Tsien et al., WO 91/06678, May 16, 1991 ("Tsien") (Ex. 1013).

Patent	References	Basis	Claim
			Challenged
'852	Dower, ⁶ Prober,	§ 103(a)	1
	Metzker ⁷		
'139	Tsien	§ 103(a)	1
'139	Dower, Prober,	§ 103(a)	1
	Metzker		
'358	Tsien	§ 103(a)	1
'358	Dower, Prober,	§ 103(a)	1
	Metzker		
'480	Tsien, Prober	§ 103(a)	1
'480	Dower, Prober,	§ 103(a)	1
	Metzker		

After institution, the Trustees of Columbia University in the City of New York ("Patent Owner" or "Columbia") filed identical Patent Owner Responses in each of the four *inter partes* proceedings. *See* Patent Owner's Response ("Resp."), Paper 31 (public version), Paper 34 (sealed version); Patent Owner's Surreply ("Surreply"), Paper 49. Petitioner filed substantively similar Reply Briefs in each of the four cases. IPR 2018-00291, Paper 45; IPR 2018-00318, Paper 47; IPR 2018-00322, Paper 45; IPR 2018-00385, Paper 44. Additionally, Petitioner filed a motion to exclude evidence (Paper 53, "Mot. Excl."), Patent Owner responded (Paper 56, "Opp. Mot. Excl."), and Petitioner provided a Reply brief (Paper 58).

We heard oral argument for the four *inter partes* review (as well as for related IPR2018-00797) on March 5, 2019, and a transcript of the hearing is

Michael L. Metzker et al., *Termination of DNA synthesis by novel 3'-modified-deoxyribonucleoside* 5'-triphosphates, 22(20) NUCLEIC ACIDS RESEARCH 4259–67 (1994) ("Metzker") (Ex. 1016).



Dower et al., U.S. Patent No. 5,547,839, Aug. 20, 1996 ("Dower")
 (Ex. 1015).

Cases IPR2018-00291, IPR2018-00318, IPR2018-00322, IPR2018-00385

part of the record of each proceeding. Paper 62 ("Transcript"). After oral argument, we requested additional briefing regarding certain estoppel issues. Paper 61. The parties provided such briefing. Papers 63 (Illumina's Supplemental Brief Regarding Estoppel ("Pet. Supp. Br.")), 64 (Patent Owner's Additional Brief ("PO Supp. Br.)), 65 (Illumina's Supplemental Reply Regarding Estopel ("Pet. Supp. Reply")), 66 (Patent Owner's Reply to Petitioner's Supplemental Brief ("PO Supp. Reply")).

B. Related Proceedings

The parties indicate that the '852 patent, '139 patent, '358 patent, and '480 patent are the subject of the following district court proceeding involving Petitioner and Patent Owner: *Trustees of Columbia University v. Illumina, Inc.*, Case No. 17-cv-973-GMS (D. Del.). Pet. 74–75; Paper 4, 1.

On March 16, 2018, Petitioner filed a Petition requesting an *inter* partes review of related U.S. Patent No. 9,868,985 B2. IPR2018-00797, Paper 1. We address that Petition in a separate decision.

The parties note that in IPR2012-00006, IPR2012-00007, and IPR2013-00011, the Board found unpatentable the challenged claims of Patent Owner's U.S. Patent Nos. 7,713,698; 7,790,869; and 8,088,575. Pet. 74–75; Paper 4, 1; see Ex. 1006; Ex. 1005; Ex. 1007; Ex. 1008 (Federal Circuit decision affirming these Board decisions). In IPR2013-00128 and IPR2013-00266, the Board found unpatentable the challenged claims of Petitioner's U.S. Patent Nos. 7,057,026 and 8,158,346. Pet. 76; see Ex. 1048; Ex. 1049; Ex. 1050 (Federal Circuit decision affirming these Board decisions). In IPR2013-00517, the Board held that Intelligent Bio-Systems, Inc. failed to demonstrate that the challenged claims of Petitioner's



Cases IPR2018-00291, IPR2018-00318, IPR2018-00322, IPR2018-00385

U.S. Patent No. 7,566,537 ("the '537 patent") were unpatentable. Pet. 76–77; *see* Ex. 1044; Ex. 1045 (Federal Circuit decision affirming this Board decision).

C. *The '852, '139, '358, and '480 Patents*

As to technical substance, only the claims of the '852, '139, '358, and '480 patents differ. For ease of discussion, we refer to the Specification of the '852 patent. The '852 patent is titled "Massive Parallel Method for Decoding DNA and RNA" and relates to a "system for DNA sequencing by the synthesis approach which employs a stable DNA template, which is able to self prime for the polymerase reaction, covalently linked to a solid surface such as a chip, and 4 unique nucleotides analogues." Ex. 1001, 4:25–30.

The '852 patent discloses that electrophoresis was a bottleneck for high-throughput DNA sequencing and mutation detection projects. *Id.* at 2:15–18. It was known to perform sequencing without electrophoresis, using a chip format and laser-induced fluorescent detection for DNA sequencing. *Id.* at 2:19–26. The '852 patent discloses that "[1]ong stretches of the same bases cannot be identified unambiguously with [a] pyrosequencing method." *Id.* at 2:44–46. The '852 patent also describes limited success in the prior art for the incorporation of 3'-modified nucleotides by DNA polymerase. *Id.* at 2:52–53.

The approach disclosed in the '852 patent is to make nucleotide analogues by linking a unique label such as a fluorescent dye or a mass tag through a cleavable linker to the

A third party also challenged the '537 patent in Cases IPR2017-02172 and IPR2017-02174, but the Board denied institution in each case. Pet. 80; Paper 10, 1.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

